Reason for request
Inclusion on the list of medicines reimbursed by National Insurance (B/5 and B/20) and approved for use by hospitals (B/5, B/20 and B/30).
Clinical Benefit
| Low |
the actual benefit of VERSATIS 5% lidocaine plasters in the treatment of PHN is low in view of its weak efficacy demonstrated versus placebo. |
Clinical Added Value
| no clinical added value |
VERSATIS offers no improvement in actual benefit compared to the current treatment strategy (IAB V). |
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
1ybzAFDgVk2aHgAT
Listen
